The U.S. Patent Trial and Appeal Board ruled Wednesday that a patent for Johnson & Johnson’s Zytiga prostate cancer drug described an obvious process, invalidating the last remaining patent blocking Argentum Pharmaceuticals LLC from making a generic version of a product that reaped $2.26 billion in sales in 2016.
Shari Redstone reportedly wants to see some fresh faces on CBS Corp.'s board, Johnson & Johnson's diabetes care unit could be sold to a Chinese consortium and Miramax's bid for the Weinstein Co. is hampering the company's potential sale.
Merck & Co. and generics manufacturer Glenmark Pharmaceuticals Inc. were hit with a putative class action in Virginia federal court Wednesday claiming an agreement to keep a generic version of cholesterol treatment Zetia off the market for five years created an unlawful monopoly.
AndroGel and other testosterone replacement therapy drugs increase the risk of dangerous blood clots in men who use them, a Yale School of Medicine physician testifying for an AndroGel user suing AbbVie Inc. told an Illinois federal jury Wednesday.
A Florida man who copped to his role in an insider trading scheme stemming from Gilead Sciences Inc.’s $11 billion acquisition of New Jersey-based Pharmasset Inc., which made the latter company’s stock value jump nearly 90 percent, was sentenced Wednesday to a year and a day in prison, federal prosecutors announced.
California’s San Joaquin County on Tuesday defended its decision to seize $77 million worth of hemp crops from a Native American tribe, a university and others, asking a California federal court to dismiss a related suit because the local ordinance it was enforcing is legal and the crops were not legal.
The Internal Revenue Service will not impose a penalty on medical device manufacturers that fail to make excise tax deposits due in the first three quarters of the year, according to an announcement on Wednesday.
Letting Louisiana bring claims that GlaxoSmithKline PLC blocked generic versions of its Flonase nasal spray, after the state was involved in a class settlement over the same allegations, would “deal a major blow” to such deals, the U.S. Chamber of Commerce told the Third Circuit on Tuesday.
Camera-shy lawyers representing Puma Biotechnology Inc. investors on Tuesday asked a California federal judge to block a Latham & Watkins LLP defense team from training a video camera on them at an upcoming deposition.
The attorney for the father of a Pennsylvania man who died from methadone toxicity after being prescribed Cephalon’s opiate painkiller “lollipop” Actiq to treat migraine headaches urged a state appeals court Wednesday to revive his lawsuit, contending that his claims were not preempted by federal law.
The House could vote as early as Thursday on a short-term government funding bill that would delay the onset of three taxes originally enacted in the Affordable Care Act health care reform law, but the legislation could stall as Republicans and Democrats disagree on what should be included in the measure.
A Massachusetts federal judge on Wednesday nixed a bid from Johnson & Johnson Services Inc. and its subsidiary DePuy Orthopaedics Inc. to escape a revised version of a suit alleging they indirectly submitted false claims to the government for faulty hip replacement devices.
Arnold & Porter Kaye Scholer LLP on Tuesday said former U.S. Sen. Christopher Dodd will join the firm in Washington, D.C., as part of its legislation and public policy group, while the former head of litigation for Eli Lilly & Co. will come aboard in its life sciences and health care regulatory practice.
The Federal Circuit on Wednesday refused to order that a patent lawsuit brought by the University of Minnesota against Gilead Sciences Inc. over hepatitis C medications be allowed to remain in the North Star State, leaving in place a ruling that found that storage lockers leased by Gilead did not create a place of business.
Aveo Pharmaceuticals Inc.’s former chief medical officer told a Massachusetts federal court Tuesday that he shouldn't have to pay a fine or be barred from leadership positions because the U.S. Securities & Exchange Commission exaggerated his alleged role in deceiving investors about Aveo's kidney cancer drug, Tivo.
The city of Philadelphia became the latest municipality to attempt to hold drug manufacturers responsible for the nation’s growing opioid crisis Wednesday, filing a state court lawsuit accusing Allergan, Purdue, Endo, Janssen and Teva of deceptive marketing.
A drugmaker challenging the U.S. Patent and Trademark Office’s controversial new policy on attorneys’ fees urged the full Federal Circuit on Tuesday to rule that the novel approach is a violation of the so-called American Rule.
In this monthly series, legal recruiting experts Amanda Brady and Amy Mallow of Major Lindsey & Africa interview law firm management from Am Law 200 firms about how they are navigating an increasingly competitive business environment. The second conversation is with Mark Usellis, chief strategy officer for Davis Wright Tremaine LLP.
The Federal Circuit on Tuesday said it won’t reconsider invalidating four Helsinn Healthcare SA nausea drug patents in a ruling over the scope of the America Invents Act's on-sale bar, but clarified that its decision isn’t as extreme as the intellectual property world feared.
The latest warning letters from the U.S. Food and Drug Administration are giving new ammunition to Allergan Inc. in its high-stakes battle with a rival drug company and putting a Chinese drugmaker on notice of “life-threatening” risks posed by its manufacturing practices.
Federal courts across the country are handing down important rulings interpreting the U.S. Supreme Court’s landmark decision on False Claims Act liability in Universal Health Services v. Escobar. As the rulings keep pouring in, stay up to speed on Law360’s latest coverage and analysis of Escobar’s impact.
Product liability defendants often seek to remove cases to federal court, because federal jurisdiction means federal pleading standards, robust expert discovery, efficiency through uniform procedural and evidentiary rules and, often, more diverse jury pools. Last year, several cases highlighted the evolving removal landscape and addressed four important questions, say Brett Clements and Amy Rubenstein of Schiff Hardin LLP.
Last year, courts issued numerous health care-related decisions interpreting the legal standards under the False Claims Act and assessing the viability of a multitude of FCA liability theories. These decisions will affect the prosecution and defense of FCA cases for years to come, says Brian Dunphy of Mintz Levin Cohn Ferris Glovsky and Popeo PC.
Although Attorney General Jeff Sessions' rescission of the Cole memo does not change federal law, negative response to the rescission across the cannabis sector and political landscape was strong, swift and unusually bipartisan, which may lead to congressional action in the future, say Jonathan Robbins and Joshua Mandell of Akerman LLP.
The volume of health care-related qui tam litigation under the False Claims Act remained robust last year. In the first of four articles on health care enforcement in 2017, Kevin McGinty of Mintz Levin Cohn Ferris Glovsky and Popeo PC discusses the important takeaways from a number of trends.
The Federal Circuit's recent decisions in Forest v. Teva and The Medicines Co. v. Mylan show that our definiteness requirements can impact patent prosecution, as well as claim interpretation and validity during an infringement action, say Brian Trinque and Giulio DeConti of Lathrop Gage LLP.
Regardless of whether new legislation is enacted, dramatic changes to the Committee on Foreign Investment in the United States have arrived. In 2017, a much “stickier” CFIUS process resulted from concerns about China and a broader worry that international trade has not always benefited the United States, say attorneys with Wilson Sonsini Goodrich & Rosati PC.
Given the incentives to organize vertically, California cannabis regulators will need to identify and challenge harmful vertical integration, but allow efficiency-improving integration in cannabis markets and revise regulations to reduce inefficiencies, says Georgina Moreno of Econ One Research Inc.
In an attempt to peek behind the corporate curtain and pick the brains of those with unrivaled access to their companies’ trade secrets, we surveyed 81 in-house attorneys who work on trade secret issues. We discovered many interesting findings — and one alarming trend, say attorneys with O’Melveny & Myers LLP.
The Committee on Foreign Investment in the United States was the subject of more focus, change and consequence in 2017 than it had been in at least a decade. It appears that the significant CFIUS developments last year soon may be followed by formal legal changes, say attorneys with Wilson Sonsini Goodrich & Rosati PC.
One of the most significant questions raised by last year's landmark Bristol-Myers Squibb decision is whether and how it applies to the claims of absent class members in the context of federal class action litigation, particularly with respect to claims that do not arise under a statute authorizing nationwide service of process, say attorneys with Morgan Lewis & Bockius LLP.